Product Description
For moderate to severe pain after abdominal surgery (Sourced from: https://www.chictr.org.cn/showprojen.aspx?proj=135457)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Center for Clinical Pharmacology, the Third Xiangya Hospital, Central South University
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Abdominal Pain|Pain Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20222714 |
CTR20222714 | P3 |
Completed |
Abdominal Pain |
2023-07-10 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20222580 |
CTR20222580 | P3 |
Completed |
Pain Unspecified |
2023-07-14 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |